On September 14, 2023 Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from "Idea to IND" (I to I), reported an agreement with BeiGene, Ltd. to expand the companies’ discovery strategic collaboration leveraging Nona’s proprietary Harbour Mice platform (Press release, Nona Biosciences, SEP 14, 2023, View Source [SID1234635171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the collaboration, BeiGene will be granted access to Nona Biosciences’ proprietary fully human transgenic mice platform Harbour Mice. Previously, in 2018, BeiGene obtained rights to use the proprietary Harbour Mice H2L2 platform for multiple antibody programs. This expanded collaboration between Nona and BeiGene will extend to the Harbour Mice HCAb (heavy chain only antibody format) platform to further improve therapeutic antibody discovery efficiency and flexibility.

"We are delighted to broaden our collaboration with BeiGene on antibody discovery. Our platform has enabled biotechnology and pharmaceutical companies as well as academia to accelerate innovative drug discovery for more than a decade. BeiGene has been a long-term partner for us, and partnership expansion is emblematic of Nona’s accumulated knowledge and expertise in drug discovery," said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences.